Диссертация (1154761), страница 17
Текст из файла (страница 17)
2008. 67: [afp]–[alp]DOI 10.1007/s00393-008-0284-7128. Stone J.H. et al. Rituximab versus cyclophosphamide for ANCA-associatedvasculitis // N Engl J Med. 2010. Vol. 363. № 3. Р. 221–32.129. Jones R.B. et al. Rituximab versus cyclophosphamide in ANCA-associatedrenal vasculitis // N Engl J Med. 2010. Vol. 363. № 3. Р.
211–20.130. Guillevin L. et al. Rituximab versus azathioprine for maintenance in ANCAassociated vasculitis // N Engl J Med. 2014. Vol. 371. № 19. Р. 1771–80.131. Koukoulaki M., Smith K.G., Jayne D.R. Rituximab in Churg–Strausssyndrome // Ann Rheum Dis. 2006. Vol. 65. № 4. Р. 557–9.132. Saech J. et al. Successful use of rituximab in a patient with Churg–Strausssyndrome and refractory central nervous system involvement //Ann Rheum Dis.
2010.Vol. 69. № 6. Р. 1254–5.101133. Cartin-Ceba R. et al. Rituximab for remission induction and maintenance inrefractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a singlecenter // Arthritis Rheum. 2012. Vol. 64. Р. 3770–8.134. Thiel J.
et al. Rituximab in the treatment of refractory or relapsingeosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome) // ArthritisRes Ther. 2013. Vol. 15. № 5. Р. 133.135. Mohammad A.J. et al. Rituximab for the treatment of eosinophilicgranulomatosis with polyangiitis (Churg– Strauss) // Ann Rheum Dis. Dec 2 2014[Epub a head of print].136. Bouldouyre M.A., Cohen P., Guillevin L.
Severe bronchospasm associatedwith rituximab for refractory Churg–Strauss syndrome // Ann Rheum Dis. 2009. Vol.68. № 4. Р. 606.137. Winchester D.E., Jacob A., Murphy T. Omalizumab for asthma // N Engl JMed. 2006. Vol. 355. Р. 1281–2.138. Abonia J., Putnam P. Mepolizumab in eosinophilic disorders // Expert Rev.Clin.
Immunol. 2011. Vol. 7. № 4. Р. 411–17.139. Kim S. et al. Mepolizumab as a steroid-sparing treatment option in patientswith Churg–Strauss syndrome // J. Allergy Clin. Immunol. 2010. Vol. 125. Р. 1336–43.140. Jennette J.C. et al. 2012 revised International Chapel Hill ConsensusConference Nomenclature of Vasculitides // Arthritis Rheum. 2013. Vol.
65. № 1. Р. 1–11.141. Piram M. et al. Effect of race ethnicity on risk, presentation and course ofconnective tissue diseases and primary systemic vasculitides // Curr Opin Rheumatol.2012. Vol. 24. Р. 193–200.142. DunoguéB.etal.FrenchVasculitisStudyGroup.Impact of cardiac magnetic resonance imaging on eosinophilic granulomatosis with polyangiitis outcomes:Alongterm retrospective study on 42 patients//Autoimmun102Rev. 2015.
Sep. 14 (9): 774-80. doi: 10. 1016/ j. autrev. 2015. 04. 013. Epub 2015 May8.143. Mukhtyar C. et al. Outcomes from studies of antineutrophil cytoplasmantibody associated vasculitis: a systematic review by the European League AgainstRheumatism Systemic Vasculitis Task Force // Ann Rheum Dis.
2008. Vol. 67. Р.1004–10.144. Samson M. et al. Long-term outcomes of 118 patients with eosinophilicgranulomatosis with polyangiitis (Churg–Strauss syndrome) enrolled in two prospectivetrials // J Autoimmun. 2013. Vol. 43. Р. 60–9.145. Grayson P.C. et al. Value of commonly measured laboratory tests asbiomarkers of disease activity and predictors of relapse in eosinophilic granulomatosiswith polyangiitis // Rheumatology. Nov 17, 2014. [Epub ahead of print].146.
Jayne D. et al. A randomized trial of maintenance therapy for vasculitisassociated with antineutrophil cytoplasmic autoantibodies // N Engl J Med. 2003. Vol.349. № 1. Р. 36–44.147. Guillevin L. et al. Rituximab versus azathioprine for maintenance in ANCAassociated vasculitis // N Engl J Med. 2014. Vol. 371. Р. 1771–80.148. Mohammad A.J. et al. Rituximab for the treatment of eosinophilicgranulomatosis with polyangiitis (Churg-Strauss) // Ann Rheum Dis.
2014.http://dx.doi.org/10.1136/annrheumdis-2014-206095 [Published online first].149. Kallenberg C.G. Churg-Strauss syndrome: just one disease entity? //Arthritis Rheum. 2005. Vol. 52. Р. 2589–93.150. Dоnvik K.K., Omdal R. Churg-Strauss syndrome successfully treated withrituximab//RheumatolInt.2010.Vol.31.Р.89–91..